Traders should monitor for potential warrant exercises, which could bring in up to $2.38 million in capital and increase shares outstanding by up to 3.07 million. The current stock price ($0.57) is below both warrant exercise prices ($0.75 and $1.09), making immediate exercise unlikely unless fundamentals improve. Watch for insider activity or news that could trigger warrant conversion.
Price Chart
Executive Summary
Silo Pharma's S-1 registration for the resale of up to 3,071,428 shares of common stock underlying previously issued warrants has become effective. The shares consist of those issuable upon exercise of investor and placement agent warrants from a private placement in October 2025. The company will not receive proceeds from the resale, but could receive up to $2.38 million if all warrants are cash-exercised.
Key Facts
- The EFFECT filing confirms that the S-1 registration statement (File No. 333-281692) became effective on April 13, 2026.
- The registration covers resale of up to 3,071,428 shares of common stock issuable upon exercise of warrants held by investors and the placement agent.
- The warrants were issued in a private placement on October 1, 2025, pursuant to a securities purchase agreement dated September 29, 2025.
- Investor Warrants: 2,857,143 shares exercisable at $0.75 per share, expiring on the 5-year anniversary of effectiveness (April 13, 2031).
- Placement Agent Warrants: 214,285 shares exercisable at $1.0938 per share, expiring September 29, 2030.
- Silo Pharma will not receive proceeds from the resale of shares by selling shareholders but may receive up to $2.38 million if all warrants are cash-exercised.
- The stock trades on Nasdaq under 'SILO' with a market cap of $6M; last sale price was $0.5690 on October 27, 2025.
Financial Impact
Potential $2.38 million in gross proceeds to the company if all warrants are cash-exercised; no proceeds from the resale itself.
Risk Factors
- Dilution risk if warrants are exercised, increasing share count by up to 3.07 million shares.
- Low stock price relative to exercise prices may reduce likelihood of warrant exercise, limiting potential capital inflow.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001163 |
| Document: 9999999995-26-001163-index.html | 9999999995-26-001163 |
| Document: 9999999995-26-001163.txt | 9999999995-26-001163 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $1.20 | awaiting T+60 | — | $1.29 (+7.50%) |
Oct 2, 2026 25d ago | 8-K | $1.49 | awaiting T+60 | — | $1.29 (−13.42%) |
Sep 18, 2026 5w ago | Press Release | $1.84 | awaiting T+60 | — | $1.29 (−29.89%) |
Aug 7, 2026 11w ago | EFFECT | $3.74 | awaiting T+60 | — | $1.29 (−65.46%) |
Jul 14, 2026 15w ago | Press Release | $5.13 $1.44 | ▼ −71.93% | ▼ −75.31% | $1.29 (−74.85%) |
Jun 30, 2026 17w ago | DEFA14A | $6.21 $1.77 | ▲ +71.50% | ▲ +75.06% | $1.29 (+79.23%) |
Jun 3, 2026 20w ago | 8-K | $6.11 $2.54 | ▼ −58.43% | ▼ −60.31% | $1.29 (−78.89%) |
Jun 1, 2026 21w ago | 8-K | $4.99 $2.59 | ▼ −48.09% | ▼ −49.32% | $1.29 (−74.14%) |
Apr 29, 2026 25w ago | Press Release | $6.74 $4.47 | ▼ −33.63% | ▼ −37.74% | $1.29 (−80.85%) |
Apr 22, 2026 26w ago | Press Release | $7.11 $4.70 | ▼ −33.90% | ▼ −38.91% | $1.29 (−81.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers